What did @olesia_loveren actually say?
The video caption, not the transcript, is doing the heavy lifting here. @olesia_loveren describes a postpartum "molecular recovery stack" built around BPC-157 and ipamorelin, framing them as a "foundation" for what she calls a "protocol of systemic upgrade." She positions this as biochemistry and "proven methods," contrasting it with superstition. The actual spoken transcript in this video is from an unrelated dietitian talking about exam gaps, which makes it impossible to fact-check her specific peptide claims from audio alone. So this review focuses on what the caption asserts: that BPC-157 and ipamorelin are evidence-based postpartum recovery tools.
The framing matters. Calling something "molecular" and "biochemistry" sounds rigorous. It is a rhetorical move, not a scientific guarantee. Let's see if the substance holds up.
Does the science back this up?
For BPC-157, the honest answer is: animal data looks interesting, human data is nearly nonexistent. Most of the excitement around BPC-157 (body protection compound 157, a synthetic pentadecapeptide derived from a gastric protein) comes from rodent studies showing accelerated tendon healing, gut repair, and reduced inflammation. Sikiric et al. (2018, Current Pharmaceutical Design) summarized decades of this preclinical work. But preclinical results routinely fail to translate. No peer-reviewed randomized controlled trial in humans has established that BPC-157 accelerates postpartum tissue repair, restores pelvic floor integrity, or reduces postpartum fatigue.
Ipamorelin is a synthetic growth hormone secretagogue that stimulates ghrelin receptors to trigger GH release. A Raun et al. (1998, European Journal of Endocrinology) study confirmed its GH-stimulating properties in animals with a cleaner side-effect profile than older secretagogues. Human clinical trials exist, mostly in GI motility contexts (Greenwood-Van Meerveld et al., 2012), not postpartum recovery. Stacking both compounds in the early postpartum period, when hormonal flux, breastfeeding status, and tissue healing overlap in ways we barely understand, has zero clinical trial backing.
What did they get wrong (or right)?
Credit where it is due: framing recovery around tissue repair and hormonal signaling rather than crash dieting or "bounce back" culture is a genuinely better instinct. Postpartum physiology is real, and the interest in peptide-based approaches is not irrational on its face.
But describing BPC-157 and ipamorelin as "proven methods" is flatly inaccurate. That word, proven, implies controlled human evidence that does not currently exist for this specific application. These compounds are not FDA-approved, not approved by any major regulatory body for postpartum use, and their safety profile in breastfeeding women is entirely unknown. No lactation pharmacokinetic studies exist for either peptide. That is not a minor footnote. Anything a breastfeeding mother takes has potential transfer into breast milk, and we have no data on what these peptides do in neonatal systems.
The "no superstition, only biochemistry" framing is also worth pushing back on. Confidence in a mechanism is not the same as evidence of an outcome. Lots of compounds have plausible mechanisms and fail in trials. Presenting a peptide stack to a postpartum audience of thousands as settled science, when it is speculative at best, is the kind of thing that should come with more caveats than a caption allows.
What should you actually know?
If you are postpartum and considering peptide therapy, here is what the current evidence actually supports as context. Growth hormone secretagogues like ipamorelin work on a real axis (the GH/IGF-1 axis), but manipulating that axis outside clinical supervision in the postpartum period introduces unpredictable variables. Prolactin, cortisol, estrogen, and progesterone are all in dramatic flux. Adding exogenous signaling molecules to that environment is not the same as taking a vitamin D supplement.
BPC-157 remains technically unscheduled in many countries but is not approved for human use by the FDA or EMA. Compounded peptide preparations vary significantly in purity and concentration. What you order is not guaranteed to be what you receive, and no regulatory body is verifying that.
Postpartum recovery does have evidence-backed interventions: pelvic floor physiotherapy (Dumoulin et al., 2018, Cochrane Review), adequate protein and iron repletion, sleep prioritization, and in some cases supervised hormonal assessment. These are less exciting to caption but they have actual human trial data.
Anyone interested in peptide therapy postpartum should work with a licensed clinician who can assess individual hormone panels, breastfeeding status, and tissue healing before any stack is considered. Social media protocols are not a substitute for that conversation.